findmyKOL
Clinical trialNCT03719586CompletedPhase 2/PHASE3Interventional

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment681Ebola Virus
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Richard T Davey, M.D.

    National Institute of Allergy and Infectious Diseases (NIAID)

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Democratic Republic of the Congo
  • Ebola Treatment Centers Throughout the Drc

    Kinshasa Gombe, Democratic Republic of the Congo

United States
  • National Institutes of Health Clinical Center

    Bethesda, Maryland, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Nov 2018
Primary completion
9 Sept 2019
Completion
18 Aug 2020
Last update posted
8 Sept 2021
Registered enrollment
681
Registry id
NCT03719586

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.